Researchers developed a deformable nanolipogel-based delivery system for CRISPR-based knockout of lipocalin 2 (Lcn2), an oncogene implicated in triple-negative breast cancer (TNBC), a leading cause of cancer-related mortality with poor prognosis, in human breast tumor cells; in a mouse model of TNBC, nanolipogel-based CRISPR knockout of Lcn2 suppressed tumor growth by approximately 77%, suggesting that the nanolipogel might represent a precise and effective delivery method for therapeutic CRISPR editing for TNBC, according to the authors.
Article #19-04697: " Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel," by Peng Guo, Jiang Yang, Jing Huang, Debra Auguste, and Marsha A. Moses.
MEDIA CONTACT: Marsha Moses, Boston Children's Hospital, Boston, MA; tel: 617-919-2207; e-mail: marsha.moses@childrens.harvard.edu
###
Proceedings of the National Academy of Sciences